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Abstract
There has been an important increase in the emergence of resistance in microbial 
population worldwide. This trajectory needs, necessarily new approaches to treat 
infectious diseases. The ability to detect and prevent the evolutionary trajectories of 
microbial resistance would be of value. Photodynamic inactivation (PDI) represents 
an efficient alternative treatment for diseases caused by viruses, which can cause 
infections well documented in various mammals. PDI can kill cells after exposure 
with the appropriate photosensitizer (PS), light of adequate wavelength combined 
with the presence of oxygen, without inducing resistance. Cytotoxic reactive 
species formed interaction with vital biomolecules leading to irreversible microbial 
inactivation. Bacteriophages can act on delivering antimicrobial agents into bac-
teria, which consist in a likely instrument for the treatment of infectious diseases. 
Non-enveloped bacteriophages are more difficult to tolerate photoinactivation than 
enveloped phages, which makes them an important model tool to evaluate the effi-
ciency of PDI therapy against viruses that cause diseases in humans. Combination of 
photosensitizers and bacteriophage therapy can be employed to eradicate biofilms, 
contributing to control of infections also caused by drug-resistant bacteria.
Keywords: bacteriophages, biofilm, microbial resistance, photodynamic therapy, 
reactive oxygen species
1. Introduction
Despite the remarkable progress in human medicine, infectious diseases of micro-
bial origin are one of main global concern to public health [1] worldwide. The relative 
unavailability of efficient drugs the misuse and/or excessive use of antimicrobials, are 
some factors that make infections harder or impossible to treat, increasing the risk of 
spreading diseases and deaths [2]. The gap in the discovery of new antibiotics over 
the decades [3, 4] also contributes to the increased risk of infectious diseases.
The emergence of antibiotic-resistant “superbugs” and their rapid global spread 
are alarming [5]. These microorganisms are members of a group known as nosoco-
mial ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.), associated 
with major risk of mortality in immunocompromised patients [6, 7]. Other high-
lights in the global list of drug-resistant priority pathogens are the third generation 
cephalosporins (3GC) resistant Escherichia coli, fluoroquinolone-resistant Neisseria 
gonorrhoeae, Streptococcus pneumoniae, Salmonella spp. and Candida auris [8, 9].
Bacteriophages
2
Drug-resistant pathogens can be transmitted through the hospital environment, 
increasing the severity in relation to Health Care-Associated Infections (HAIs) [10], 
also causing an important economic impact especially in developing countries. 
In these countries, the infectious diseases are more prevalent, and the prevention 
measures requires the use of drugs that maximize costs [7]. Given this scenario, 
effective antibiotics and strategies to combat antimicrobial resistance, prevent the 
high number of deaths each year and an economic crisis worldwide become urgent 
[11, 12]. This chapter describes photodynamic treatment, bacteriophages utilization 
and the combination of both as alternative therapies for minimize the excessive 
exposure of patients to antibiotic and risks of multi-resistant strains development.
2. Photodynamic therapy: past
The therapeutic potential of light has been used for hundreds of years by the 
ancient civilizations in Egypt, China, and India. Also, over 3000 years ago, light 
was used in conjunction with reactive chemicals to treat various conditions such 
as vitiligo, psoriasis, and some types of skin cancer. In China, it was introduced 
by Lingyan Tzu-Ming in the first century b.C., and, four centuries later, became a 
ritual practice in which it was based on exposing a piece of green paper containing 
a red dye and exposed to sunlight, then it was soaked in water and ingested right 
after [13, 14].
In the last few decades, Photodynamic therapy (PDT) has emerged as a promis-
ing intervention treatment for cancer therapy. However, it is widely used in the 
removal of small vessels and in the treatment of microbial infections [15]. Still, the 
first concepts of the nature of light emerged in the 17th century. Preliminary work 
on the properties of light, such as that of Christiaan Huygens, who used wave theory 
to explain the reflection and refraction of light in 1690, and, later, the discovery of 
the properties of electricity and magnetism, in the early 19th century [16, 17].
In fact, quantum theory started when Max Planck, in 1900 published an article 
that explained the spectral distribution of Blackbody Radiation, which perfectly 
fitted the laws of thermodynamics with the laws of electromagnetism. And in the 
same year, Oscar Raab was scientifically proven to have the beneficial effects of 
light. In his experiment, it was observed that the combination of light with the 
acridine dye (Figure 1) was lethal for Paramecium species. In the same year, the 
French neurologist, Jean Prime, discovered that oral eosin, used to treat patients 
with epilepsy, could cause dermatitis when exposed to sunlight [16, 18].
According to electrodynamic theory, light consists of an oscillating electromag-
netic field that propagates as a wave through a vacuum or through a medium [16]. 
This means that when light propagates through space, it behaves like a wave, while 
when interacting with matter, it behaves like particles [16, 17, 19]. This concept was 
described by Einstein in 1905 based on the theories of Planck and Hertz for the expla-
nation of the photoelectric effect (Eq. (1)). For that, Einstein assumed that light had 
Figure 1. 
Chemical structure of acridine.
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a corpuscular nature, that is, it would be formed by small bundles of energy (quanta) 
called photons. Einstein also proposed the existence of a dependency relationship 
between the photoelectric emission and the frequency of incident radiation. For this 
theory to be valid, light could not be considered as a wave, but as a particle [17, 20].
Finally, in 1924, de Broglie created the hypothesis of wave-particle duality, which 
was soon recognized by Erwin Schrödinger who developed the wave propagation 
equation in matter in 1926 (Eq. (2)). Still during this period, other important scientists 
contributed to the establishment of quantum mechanics such as, for example, Max Born 
(Matrix Quantum Mechanics), Paul Dirac (Movement of sub-atomic particles), Werner 
Heisenberg (Uncertainty Principle) and Wolfgang Pauli (Principle of Exclusion) [20].
Equation 1: According to Einstein, each photon has an energy proportional to 
the frequency of light.
 E c /photon h= λ  (1)
E = de um quantum energy of light
h = Planck constant = 6,63 x 10–34 J.s
c = Speed of light (3 × 1010 cm/s)
λ = Frequency of light (Hz)
Equation 2: Erwin Schrödinger allows to determine to find the wave func-










− ∇ Ψ + Ψ =
∂
   (2)
ħ = Planck constant (6,63 x 10–34 J.s) squared reduced
m = Particle mass
∇ = Ψ Laplacian – Spatial variation of the wave function
Ψ = Wave function
V = V potential that acts on the particle
i = Imaginary number given by the square root of −1
ət = Variation of wave function Ψ over time
In the same year, Policard [21] conducted a study where he detected the pres-
ence of porphyrins in high concentrations in malignant tumors. These, completely 
non-toxic, were able to destroy the tumor tissue in the presence of visible light and 
oxygen [21].
Later, in 1950 Schwartz demonstrated that the long-lasting phototoxic effect was 
not promoted only by hematoporphyrin. The action occurred due to an oligomeric 
mixture together with it. Since hematoporphyrin is eliminated quickly from the 
body, Schwartz enriched the oligomer mixture and this preparation was called 
hematoporphyrin derivative (HpD), which contains in addition to monomers, 
oligomers containing two to nine units of porphyrin [14, 22].
In the study conducted by Weishaupt [23], it was demonstrated that the destruc-
tion of tumor cells was due to the formation of singlet oxygen molecules.
Finally, in 1993, Photofrin ® (Axcan Pharma Inc., Canada) was approved for the 
treatment of superficial bladder cancer by the Canadian Health Protection Branch. 
Subsequently, in 1998 the Food and Drug Administration (FDA) authorized PDT in 




PDT consists of a photochemical reaction between a photosensitizing agent and 
the oxygen that selectively destroys the target tissue, constituting an alternative 
modality clinically approved by several health agencies in many countries [25–29]. 
The photodynamic effect consists of causing a powerful and sustained photochemical 
reaction between light at a given wavelength, the photosensitizer (PS) and oxygen in 
the target tissue. Consequently, after the irradiation of light, PS converts O2 into cyto-
toxic reactive oxygen species (ROS), where cell death can occur through mechanisms 
such as apoptosis, necrosis, or autophagy (Figure 2). However, recent studies have 
demonstrated the existence of other mechanisms with characteristics of necrosis and 
apoptosis. These new pathways of cell death, collectively called regulated necrosis, 
include a variety of processes triggered by different stimuli [14, 30].
Figure 2. 
Basic scheme of the photodynamic reaction. (A) Formation of ROS. (B) Porphyrin group of photosensitizer 
absorbs a photon that excites it to the short-lived singlet state and may decay by non-radioactive relaxation 
with heat emission or fluorescence emission to the long-lived triple state. In this triplet state, PS can interact 
with molecular oxygen in two ways, type-1 and type-2, leading to the formation of oxygen radicals and singlet 
oxygen [31].
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The light is formed by subatomic particles given off by atoms and are endowed 
with high luminous energy, and energy differences result in different colors called 
photons. The laser (Light Amplification by Stimulated Emission of Radiation) 
consists of a monochromatic, non-ionizing and highly concentrated beam of 
light. Each wave has identical coherence in size and physical shape along its axis, 
producing a specific form of electromagnetic energy. This wave is characterized by 
spatial coherence, that is, the beam can be well defined. The intensity and ampli-
tude of the beam follow the curve of the Gaussian beam bell as most of the energy 
is in the center, with a rapid drop at the edges. There is also a temporal coherence, 
which means that the emission of the single wavelength has identical oscillations 
over a period. The final laser beam starts in a collimated form and can be emitted 
over a long distance in this way. However, bundles emanating from optical fibers 
generally diverge at the tip. When using lenses, all the beams can be precisely 
focused, and this monochromatic and coherent beam of light energy can achieve 
the treatment goal [16, 32, 33].
Photosensitizing agents (PS) consist of molecules in the singlet state in their 
fundamental state because they have two electrons with opposite spins that allow 
the transport and transfer of light energy for a chemical reaction, where each PS 
has unique characteristics for successful activation such as wavelength and creep 
intensity [34–36].
Most of them are derived from endogenous dyes and are characterized by not 
being toxic to cells. The molecular structure of most PSs used in PDT is based on a 
tetrapyrrol skeleton. This type of structure occurs naturally in several important 
biomolecules, such as heme, chlorophyll, and bacteriochlorophyll, being called 
“pigments of life” [36]. Therefore, PSs based on porphyrin structures satisfy most 
of the desirable properties of PSs, such as the high efficiency of singlet generation 
(1O2), absorption of the higher wavelengths of the electromagnetic spectrum and a 
relatively greater affinity for malignant cells, in addition, due to the internal dimen-
sions of the macrocycle cavity and the chelate effect, the porphyrin macrocycle can 
coordinate transition metals in various oxidation states [36].
4. Bacteriophages and PDT
Resistance to antibiotics spreads rapidly in relation to the discovery of new 
compounds and their introduction into clinical practice. In addition, the increase 
in bacterial adaptation can be directly correlated to the scarcity of new classes 
of antimicrobial agents. In the last decades, synthetic tailoring has been the 
main strategy to improve the nuclear scaffolding established through analog 
generation. Although this approach has been beneficial, this research has faced 
a ‘Discovery Void’ for 30 years, of which no new class of drugs effective against 
problematic ESKAPE pathogens. In addition, pathogenic microorganisms gener-
ally have the ability to form biofilms. This cellular superstructure may exhibit 
greater resistance to antibiotics and cause serious and persistent health problems 
in humans [37–39].
Bacteriophages (phages) are ubiquitous viruses which cause no harm to human or 
animal cells but are capable to specifically infect, replicate, and kill bacteria [40, 41]. 
Bacteriophages have been described for delivering successfully antimicrobial agents 
into bacteria, which consist in a potential alternative for the treatment of infectious 
diseases [42, 43] caused by bacteria.
The first in vivo evidence of effective phage therapy against Klebsiella pneu-
moniae, one of Gram-negative bacterium of ESKAPE group listed in the critical pri-
ority tier [44, 45] as serious opportunist in nosocomial infections in the respiratory 
Bacteriophages
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and urinary tracts, wound sites and blood [46], was demonstrated by Anand et al. 
[47]. The authors observed significant reduction in the lung lesion severity in the 
mouse model, suggesting the efficacy of a novel lytic phage VTCFPA43 therapy 
against virulent K. pneumoniae infection by the intranasal route.
According to [48, 49], the delivery systems based on a phage-carrying PS 
exhibit increased effective killing by the concentrated fluence at the bacterial cell 
wall, and consequently, reduced side damage to the indigenous microbiota by 
the site singlet oxygen. Moreover, they investigated the photodynamic effects of 
the photosensitizer tin (IV) chlorin e6 (SnCe6) (Figure 3A) covalently linked to 
phage 75 on several strains of S. aureus, including methicillin- and vancomycin-
intermediate strains. Pathogens such as Methicillin-resistant Staphylococcus aureus 
(MRSa) show that antibiotic resistance rates are surpassing 50% in 5 out of 6 world 
regions of the World Health Organization (WHO) [37, 50]. Results showed that 
the phage 75 conjugated with SnCe6 was not capable to damage human epithelial 
cells whereas potently showed bactericide effect against vancomycin-intermediate 
and MRSa. Additionally, other exogenous photosensitizers (protoporphyrin IX 
and protoporphyrin diarginate) have been successfully in vitro evaluated against 
clinical strains of MRSa [51].
Acinetobacter baumannii is other important Gram-negative bacterium 
multidrug-resistant involved in nosocomial infections [51]. Due its capacity to 
form biofilms, they have the capacity to survive and persist in intensive care unit 
environment and medical devices [52], what also make of A. baumannii one of 
critical-priority pathogens encompassing the ESKAPE group, for which new 
antibiotics and combating strategies are urgently needed [11, 12]. In this way, 
[53] used for the first time the strategy of combining of cationic photosensitizer 
(NB), structurally modified to produces ROS, and bacteriophages (APB)-based 
photodynamic antimicrobial agent (APNB) for eradication biofilm formed by 
multi-drug resistant A. baumannii. Both in vitro and in vivo assays demonstrated 
that APBN was efficient to treat A. baumannii infection, including being more 
efficient than some antibiotics when evaluated in vivo. These results demon-
strated the potential of APNB in combating multidrug-resistant bacteria and 
biofilm ablation.
Candida albicans and more recently C. auris are opportunistic polymorphic 
fungal pathogens, which exhibits almost 40% mortality rates for superficial and 
systemic infections in humans [54–57]. Likewise, the increasing occurrence of 
antibiotic-resistant among C. albicans strains, demands new approaches to control 
this life-threatening pathogen [58]. In [59], it reported the photodynamic inactiva-
tion of C. albicans by the Pheophorbide A (PPA) (Figure 3B), a chlorophyll-based 
Figure 3. 
Chemical structure of (A) SnCe6 and (B) PPA.
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photosensitizer crosslinked associated with single-chain variable-fragment phage 
(JM), which possesses high affinity to β-glucanase mannoprotein (MP65), an essen-
tial cell-wall mannoprotein of C. albicans. The complex PPA-JM-phage was capable 
to induce a caspase-dependent apoptosis pathway in C. albicans.
The second-generation of PSs exhibits improved photophysical properties in 
relation to first-generation PSs, which halogens or other substituents are added in 
the meso- positions of the porphyrin macrocycle. These porphyrins present a better 
activation of the ring, since the halogens act as removers of electronic density of the 
ring [18]. Chlorins, which are essentially reduced porphyrins derived from chloro-
phyll bacteria fetophorides, stable derivatives of chlorophyll varieties that are found 
in bacteria, are related to porphyrins and are simple to produce. Phthalocyanines 
and naphthalocyanines, which are derived from azaporphyrin, have high stability, 
and selectivity [36].
On the other hand, light absorption capacity is an important factor, since most 
tissues present a comparatively low absorption in the spectral range that extends 
from 500 nm to about 1500 nm (Table 1). This wavelength range is popularly 
known as the therapeutic window or the diagnostic window (Figure 4) [26, 60].
Tissue Wavelength (nm)
630 632.8 675 780 835
Optical penetration depth (mm)
Blood 0.19 0.28 0.42 0.51
Mammary tissue 2.59 2.87 3.12 3.57
Brain (postmortem) 0.92 1.38 2.17 2.52
Brain 1.6
Lung 0.81 1.09 1.86 2.47
Table 1. 
Capacity penetration (mm) of light in different tissues. Adapted from [61].
Figure 4. 
Electromagnetic spectrum and their respective wavelengths in the region of visible light as a function of the 
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5. Concluding remarks
According to the theoretical bases discussed here, PDT deserves a more central 
position in the treatment of infectious diseases, since several studies report its 
enormous potential and applicability on several fronts.
Bacteriophages can act for delivering antimicrobial agents into bacteria, which 
consist in a potential and efficient alternative for the treatment of infectious diseases.
Delivery systems based on a phage-carrying PS exhibit increased effective kill-
ing by the concentrated fluence at the bacterial cell wall, and consequently, reduced 
side damage to the indigenous microbiota by the site singlet oxygen.
The discovery of new PSs and formulations based on nano structures, in addi-
tion to the use in conjunction with already established protocols, PDT shows itself 
as a strong alternative to conventional treatments.
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